21. DLE trusted by industry leaders
“What they have been able to accomplish in 2 weeks makes you forget that you are
watching it on a mobile device and think you are watching it on a game console”
Scott Forstall, SVP iOS iPhone, Apple Keynote
“Digital Legends was able to push the limits in the development of Icebreaker ”
Torsten Reil, CEO, Natural Motion on Icebreaker
21
22. Karisma: The most-advanced 3D game development
environment for multi-platform mobile devices
Comprehensive development environment including
libraries, tools, game engine and diagnostics
Completely OS and device agnostic: Supporting all
relevant mobile platforms, connected TVs as well as
Flash11 and browser (Chrome)
Native performance for all popular mobile/portable
platforms
(iPhone/iPad, Android, Symbian, WinMo, Linux, Meego, B
ADA and PSP)
Most agile in industry in supporting new devices and
graphics technology (e.g. OpenGL 2.0)
Young code base (4 years) with zero legacy unlike
competitors: 100% optimized for mobile
Systematically 18 months ahead of closest competitors, very few competitors worldwide with access to similar high-
performance technology required to deliver high-end 3D games
22
23. Strong underlying KPIs confirm DLE’s ability to create successful
games
Battlefield Bad Company 2 (2010) Icebreaker (2011)
Total downloads since launch Nearly 2 Million downloads in 7 Total downloads since launch Over 200,000 paid
(in Million) months (in Million) downloads in under a month
Consistently in top 10 adventure since launch
games, #1 globally for all apps in Ranked 8 in USA, top 10 in 14
Christmas 2010 countries
To be pushed by key US carriers #2 for sports games on
(Xperia PLAY) in 2011 AppStore in June 2011
iPad version (launched June 2011) Rated 4+ of 5 on iTunes
already #1 in most key markets Featured App (chosen by
(UK, Germany) Apple) in over 60 countries
Featured App (chosen by Apple) in
over 60 countries Weeks since launch
Bruce Lee Dragon Warrior (2010) Kroll (2008)
Key figures (DLE)
Total installs since launch Game played by close to 2,5 Close to 850,000 players
(in Million) #1 in Japanese AppStore top 5
Million gamers Nearly 10 Million players
#1 in Japan and UK, #2 in in most European countries
USA, top 10 in major Featured App (chosen by One #1 game world wide
European countries, #1 in Apple) in over 60 countries Three #1 games in Japan
Samsung Bada store First OpenGLES 2.0 title Five top 25 games in USA
Multi-platform success story: Samsung Bada #1 free
Across all platforms incl. downloads 15 awards and nominations
iPhone, iPad, Bada, Android PocketGamer Silver, IMGA
and Xperia PLAY People’s Choice Awards
iPad App of the week in June
2011
23
es based on publically available sources. All data per H1 2011
24. Explosive recent top line growth confirms major market
traction – growth to accelerate going forward
Revenue and EBITDA 2009-2014F (in € Million) Achievements
Revenues
EBITDA 10 Million players
Very high revenue growth
Endorsed and trusted
by industry leaders
Best-in-class multi-platform
technology platform
Top ranked in various
App Stores
2009 2010 2011 2012F 2013F 2014F 2015F
24
25. Key value considerations
Part of a $11 billion mobile gaming market opportunity
Proprietary state-of-the-art technology
Riding on top of key trends: mobile, 3D, multiplayer, multi-platform, multi-
screen, virtual goods, gamification
Competitive advantage in addressing all platforms with the best 3D performance
High-end games validated by customers, hardware vendors such as Apple, AMD and
Intel. as well as publishers such as EA, Disney and Natural Motion
Highly skilled management with experienced R&D team
Unique expertise and know-how to pioneer the development of games for new
generation devices like tablets, gaming handhelds and TV Set-top Boxes
25
26. THANK YOU!
Xavier Carrillo-Costa
CEO
xcc@digital-legends.com
26
29. New medicines based on the
Coffee Pharmacology
Company Presentation
Spain Startup & Investor Summit - Madrid
6-8 June 2012
30. Adenosine Receptors: The Basis of the
Caffeine Pharmacology
Hyperactivity Diuretic
CAFFEINE
Antiarrythmic Bronchodilation
31. Adenosine Receptors: The Basis of the
Caffeine Pharmacology
Caffeine exert a strong
bronch0dilatory effects in
humans: Potential new
therapies for asthma
Hyperactivity (A2a receptors)
People consuming high
Caffeine levels daily shows
less risk to develop
Neurodegenerative CAFFEINE
Diseases: Potential new
therapiest for Parkinson and
Alzheimer Diseases
Bronchodilation (A1 receptors)
32. Pipeline Status at the proposed
next financing round and Exit
2012 2013 2014
Phase Ia Phase I Phase IIa
completed completed completed
PBF-509:
PD Treatment
Phase I Phase IIa
IND Filed completed completed
PBF-680:
Asthma Treatment
Financing Round of 5Mio € seeked in two tranches: Company Exit
2,5 Mio. € 2013 to support Phase I clinical trials Company Value:
2,5 Mio. € 2014 to support Phase IIa clinical trials
150 Mio.€
33. Excellent Market Potential
RECENT DEALS
Projects involving adenosine receptors modulators originated over 50 deals and over $300
Billions investment from the Pharmaceutical companies in the last three years e.g:
- Vernalis/ Biogen deal on A2a antagonists for PD (15 Mio € upfront after Phase I)
- Synosia/Roche deal on A2a antagonists for PD (40 Mio € upfront after Phase IIa)
- Merck acquisition of Novacardia on A1 antagonist (350 Mio USD)
TARGET INDICATION MARKET
The therapeutic indications targeted by our programs represent high unmet
medical needs with an excellent market potential:
Estimated Peak Sales (in Mio €)
PBF-680 (Asthma): 3000
PBF-509 (Parkinson's Disease): 600
34. The Team
Management
• Julio Castro, PhD (CEO):
– PhD in Chemistry at the University of Konstanz, Germany (1998)
– > 10 years of pharmaceutical research experience (Bayer, Almirall and Oryzon Genomics)
• Juan Camacho, PhD (CSO)
– PhD in Chemistry at the University of Jena, Germany (1997)
– > 10 years of pharmaceutical research experience (IBML, Jenapharm)
• Nahomi Castro, PhD (Clinical Project Leader)
– PhD in Biology at the University of Frankfurt, Germany (2000)
– > 5 years of experience leading preclinical and clinical programs (Adavancell, Salutis)
• Jose Maria Echarri: (Board Member/Interim CFO)
– Graduated in economy and enterprise administration at the University of Barcelona
– Former CFO of Oryzon Genomics
– CEO of Inveready
35. All the elements of a successful Biotech
Specialized
Bio-investors
A well defined A well trained and
exit strategy well advised team
PALOBIOFARMA
Attractive Market A solid IP
Potential
A diversified
promising Pipeline of
competitive products